Cargando…
Peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in Alzheimer’s disease
BACKGROUND: Cholinesterase inhibitors remain the first line therapy for people with mild to moderate Alzheimer’s disease (AD). Response is modest and difficult to predict from pre-treatment characteristics. We hypothesise that skin vascular response to iontophoresis of acetylcholine, which is partly...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500049/ https://www.ncbi.nlm.nih.gov/pubmed/31053120 http://dx.doi.org/10.1186/s12883-019-1316-4 |
_version_ | 1783415879998898176 |
---|---|
author | Connelly, Peter J. Adams, Fiona Tayar, Ziad I. Khan, Faisel |
author_facet | Connelly, Peter J. Adams, Fiona Tayar, Ziad I. Khan, Faisel |
author_sort | Connelly, Peter J. |
collection | PubMed |
description | BACKGROUND: Cholinesterase inhibitors remain the first line therapy for people with mild to moderate Alzheimer’s disease (AD). Response is modest and difficult to predict from pre-treatment characteristics. We hypothesise that skin vascular response to iontophoresis of acetylcholine, which is partly determined by the level of cholinesterase activity, may be a pre-treatment measure that could predict response to therapy. METHODS: Twenty-four people with probable AD underwent iontophoresis of acetylcholine to the volar surface of the forearm skin prior to treatment with a cholinesterase inhibitor. The peak skin vascular response and the resolution to baseline levels were measured using laser Doppler perfusion imaging. Response to treatment was assessed after 6 months using criteria from the National Institute for Health and Care Excellence (NICE) and iontophoresis with acetylcholine was repeated. Blindness between clinical and laboratory assessments was maintained. RESULTS: Fourteen out of twenty-four people responded to treatment using NICE criteria. By comparison to non-responders, responders to treatment had a faster resolution to baseline from acetylcholine-induced vasodilation prior to treatment, which slowed with treatment. In this pilot study there was a high level of accuracy in the classification of response using this variable. No baseline cognitive or functional measures discriminated end-point responders from non-responders. CONCLUSION: Cholinesterase inhibitors are well tolerated but the number of people with adverse effects would be reduced if it was possible to predict response. The role of vasodilator response to acetylcholine and recovery as a potential biomarker for efficacy of treatment should now be evaluated and may possibly be of relevance in stratifying samples for interventional studies in AD and other forms of dementia. We feel that a more definitive study is now justified. |
format | Online Article Text |
id | pubmed-6500049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65000492019-05-09 Peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in Alzheimer’s disease Connelly, Peter J. Adams, Fiona Tayar, Ziad I. Khan, Faisel BMC Neurol Research Article BACKGROUND: Cholinesterase inhibitors remain the first line therapy for people with mild to moderate Alzheimer’s disease (AD). Response is modest and difficult to predict from pre-treatment characteristics. We hypothesise that skin vascular response to iontophoresis of acetylcholine, which is partly determined by the level of cholinesterase activity, may be a pre-treatment measure that could predict response to therapy. METHODS: Twenty-four people with probable AD underwent iontophoresis of acetylcholine to the volar surface of the forearm skin prior to treatment with a cholinesterase inhibitor. The peak skin vascular response and the resolution to baseline levels were measured using laser Doppler perfusion imaging. Response to treatment was assessed after 6 months using criteria from the National Institute for Health and Care Excellence (NICE) and iontophoresis with acetylcholine was repeated. Blindness between clinical and laboratory assessments was maintained. RESULTS: Fourteen out of twenty-four people responded to treatment using NICE criteria. By comparison to non-responders, responders to treatment had a faster resolution to baseline from acetylcholine-induced vasodilation prior to treatment, which slowed with treatment. In this pilot study there was a high level of accuracy in the classification of response using this variable. No baseline cognitive or functional measures discriminated end-point responders from non-responders. CONCLUSION: Cholinesterase inhibitors are well tolerated but the number of people with adverse effects would be reduced if it was possible to predict response. The role of vasodilator response to acetylcholine and recovery as a potential biomarker for efficacy of treatment should now be evaluated and may possibly be of relevance in stratifying samples for interventional studies in AD and other forms of dementia. We feel that a more definitive study is now justified. BioMed Central 2019-05-03 /pmc/articles/PMC6500049/ /pubmed/31053120 http://dx.doi.org/10.1186/s12883-019-1316-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Connelly, Peter J. Adams, Fiona Tayar, Ziad I. Khan, Faisel Peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in Alzheimer’s disease |
title | Peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in Alzheimer’s disease |
title_full | Peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in Alzheimer’s disease |
title_fullStr | Peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in Alzheimer’s disease |
title_full_unstemmed | Peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in Alzheimer’s disease |
title_short | Peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in Alzheimer’s disease |
title_sort | peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in alzheimer’s disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500049/ https://www.ncbi.nlm.nih.gov/pubmed/31053120 http://dx.doi.org/10.1186/s12883-019-1316-4 |
work_keys_str_mv | AT connellypeterj peripheralvascularresponsestoacetylcholineasapredictivetoolforresponsetocholinesteraseinhibitorsinalzheimersdisease AT adamsfiona peripheralvascularresponsestoacetylcholineasapredictivetoolforresponsetocholinesteraseinhibitorsinalzheimersdisease AT tayarziadi peripheralvascularresponsestoacetylcholineasapredictivetoolforresponsetocholinesteraseinhibitorsinalzheimersdisease AT khanfaisel peripheralvascularresponsestoacetylcholineasapredictivetoolforresponsetocholinesteraseinhibitorsinalzheimersdisease |